207 related articles for article (PubMed ID: 18715028)
1. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma.
Chaerkady R; Harsha HC; Nalli A; Gucek M; Vivekanandan P; Akhtar J; Cole RN; Simmers J; Schulick RD; Singh S; Torbenson M; Pandey A; Thuluvath PJ
J Proteome Res; 2008 Oct; 7(10):4289-98. PubMed ID: 18715028
[TBL] [Abstract][Full Text] [Related]
2. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues.
Sun W; Xing B; Sun Y; Du X; Lu M; Hao C; Lu Z; Mi W; Wu S; Wei H; Gao X; Zhu Y; Jiang Y; Qian X; He F
Mol Cell Proteomics; 2007 Oct; 6(10):1798-808. PubMed ID: 17627933
[TBL] [Abstract][Full Text] [Related]
3. Identification of a protein signature for predicting overall survival of hepatocellular carcinoma: a study based on data mining.
Wu ZH; Yang DL
BMC Cancer; 2020 Aug; 20(1):720. PubMed ID: 32746792
[TBL] [Abstract][Full Text] [Related]
4. Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma.
Qi Y; Xu F; Chen L; Li Y; Xu Z; Zhang Y; Wei W; Su N; Zhang T; Fan F; Wang X; Qin X; Zhang L; Liu Y; Xu P
Oncotarget; 2016 Oct; 7(42):68242-68252. PubMed ID: 27626164
[TBL] [Abstract][Full Text] [Related]
5. Identification by differential tissue proteome analysis of talin-1 as a novel molecular marker of progression of hepatocellular carcinoma.
Kanamori H; Kawakami T; Effendi K; Yamazaki K; Mori T; Ebinuma H; Masugi Y; Du W; Nagasaka K; Ogiwara A; Kyono Y; Tanabe M; Saito H; Hibi T; Sakamoto M
Oncology; 2011; 80(5-6):406-15. PubMed ID: 21846996
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery.
Niu D; Feng H; Chen WN
J Proteomics; 2010 May; 73(7):1283-90. PubMed ID: 20188222
[TBL] [Abstract][Full Text] [Related]
7. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics.
Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J
J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406
[TBL] [Abstract][Full Text] [Related]
8. Quantitative proteomics reveal up-regulated protein expression of the SET complex associated with hepatocellular carcinoma.
Li C; Ruan HQ; Liu YS; Xu MJ; Dai J; Sheng QH; Tan YX; Yao ZZ; Wang HY; Wu JR; Zeng R
J Proteome Res; 2012 Feb; 11(2):871-85. PubMed ID: 22082227
[TBL] [Abstract][Full Text] [Related]
9. MALDI imaging-based classification of hepatocellular carcinoma and non-malignant lesions in fibrotic liver tissue.
Marquardt C; Tolstik T; Bielecki C; Kaufmann R; Crecelius AC; Schubert US; Settmacher U; Stallmach A; Dirsch O
Z Gastroenterol; 2015 Jan; 53(1):33-9. PubMed ID: 25594705
[TBL] [Abstract][Full Text] [Related]
10. Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye.
Fujii K; Kondo T; Yokoo H; Yamada T; Iwatsuki K; Hirohashi S
Proteomics; 2005 Apr; 5(5):1411-22. PubMed ID: 15751005
[TBL] [Abstract][Full Text] [Related]
11. Tissue-based quantitative proteome analysis of human hepatocellular carcinoma using tandem mass tags.
Megger DA; Rosowski K; Ahrens M; Bracht T; Eisenacher M; Schlaak JF; Weber F; Hoffmann AC; Meyer HE; Baba HA; Sitek B
Biomarkers; 2017 Mar; 22(2):113-122. PubMed ID: 27467182
[TBL] [Abstract][Full Text] [Related]
12. In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery.
Zhang J; Hao N; Liu W; Lu M; Sun L; Chen N; Wu M; Zhao X; Xing B; Sun W; He F
Br J Cancer; 2017 Nov; 117(11):1676-1684. PubMed ID: 29024941
[TBL] [Abstract][Full Text] [Related]
13. Investigation of Pokemon-regulated proteins in hepatocellular carcinoma using mass spectrometry-based multiplex quantitative proteomics.
Bi X; Jin Y; Gao X; Liu F; Gao D; Jiang Y; Liu H
Eur J Mass Spectrom (Chichester); 2013; 19(2):111-21. PubMed ID: 24261083
[TBL] [Abstract][Full Text] [Related]
14. Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma.
Xu X; Liu Z; Wang J; Xie H; Li J; Cao J; Zhou L; Zheng S
Oncotarget; 2016 Mar; 7(12):13730-41. PubMed ID: 26883192
[TBL] [Abstract][Full Text] [Related]
15. Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology.
Melle C; Kaufmann R; Hommann M; Bleul A; Driesch D; Ernst G; von Eggeling F
Int J Oncol; 2004 Apr; 24(4):885-91. PubMed ID: 15010826
[TBL] [Abstract][Full Text] [Related]
16. Significant Down-Regulation of Urea Cycle Generates Clinically Relevant Proteomic Signature in Hepatocellular Carcinoma Patients with Macrovascular Invasion.
Cao Y; Ding W; Zhang J; Gao Q; Yang H; Cao W; Wang Z; Fang L; Du R
J Proteome Res; 2019 May; 18(5):2032-2044. PubMed ID: 30901224
[TBL] [Abstract][Full Text] [Related]
17. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies.
Ritorto MS; Borlak J
J Proteome Res; 2011 Jul; 10(7):3012-30. PubMed ID: 21644509
[TBL] [Abstract][Full Text] [Related]
18. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways.
Sun S; Lee NP; Poon RT; Fan ST; He QY; Lau GK; Luk JM
Liver Int; 2007 Oct; 27(8):1021-38. PubMed ID: 17845530
[TBL] [Abstract][Full Text] [Related]
19. Use of CD34 and factor VIII to diagnose hepatocellular carcinoma on fine needle aspirates.
Gottschalk-Sabag S; Ron N; Glick T
Acta Cytol; 1998; 42(3):691-6. PubMed ID: 9622689
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma.
Park KS; Kim H; Kim NG; Cho SY; Choi KH; Seong JK; Paik YK
Hepatology; 2002 Jun; 35(6):1459-66. PubMed ID: 12029631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
